Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections
Status:
Not yet recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
Due to rising antibiotic resistance, there has been a focus on non-antibiotic prophylactic
measures for postmenopausal patients with recurrent urinary tract infections (rUTI), one of
which is the safe and efficacious option of vaginal estrogen therapy. Standard application of
vaginal estrogen cream entails intravaginal application of the cream twice a week, but some
providers counsel patients with rUTI to apply a small, pea-sized amount to the periurethral
area. This ideally reduces the amount of vaginal estrogen used while attaining a similar
effect. However, to date, there is no data to prove that the periurethral technique of
application is similar or non-inferior to intravaginal application in preventing UTI.